A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
Status:
Completed
Trial end date:
2019-02-26
Target enrollment:
Participant gender:
Summary
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The
blinded phase only will be described in this record. Participants will receive 1 of 2 doses
of GWP42003-P or matching placebo. The primary clinical hypothesis is that there will be a
difference between GWP42003-P and placebo in their effect on seizure frequency.